Los Angeles, CA -- (SBWIRE) -- 12/10/2018 -- Micafungin (trade name Mycamine) is an echinocandin antifungal drug used to treat and prevent invasive fungal infections including candidemia, abscesses and esophageal candidiasis. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.

In 2013, Japan was the largest consumption place, with a consumption market share nearly 35.40%. In 2017, North America is the largest consumption place with the consumption market share of 28.98%.

Astellas is the leader of the industry, and it holds key technologies and patents, with high-end customers; has been formed in the monopoly position in the industry.

In 2018, the market size of Micafungin Sodium for Injection is 380 million US$ and it will reach 310 million US in 2025.

In this report, 2017 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Micafungin Sodium for Injection.

This study researches the market size of Micafungin Sodium for Injection in United States, European Union and China, presents the Micafungin Sodium for Injection sales, revenue, market share and growth rate by companies, type and application, history breakdown data from 2013 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the sales, revenue, market share and growth rate for the top players, key data from 2013 to 2018.

Request Sample Report Copy@ https://www.qyresearch.com/sample-form/form/839084/global-united-states-european-union-and-china-micafungin-sodium-for-injection-market

In United States, European Union and China market, the following companies are covered:

Astellas

...

Market Segment by Product Type

50 mg Single-use Vial

100 mg Single-use Vial

Market Segment by Application

Candidemia

Respiratory Mycosis

Gastrointestinal Mycosis

Key Regions split in this report:

United States

China

European Union

Rest of World (Japan, Korea, India and Southeast Asia)

Buy Full market Report Now, Report delivery time within 24 hours @ https://www.qyresearch.com/settlement/pre/9f259f542f72995255faddbccad0892d,0,1,Global%20United%20States%252C%20European%20Union%20and%20China%20Micafungin%20Sodium%20for%20Injection%20Market%20Research%20Report%202018-2025

About QYResearch
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.